高级检索
中华结核和呼吸杂志
期刊首页
过刊列表
高级检索
稿件发表
• 年度综述 •
ENGLISH ABSTRACT
呼吸感染性疾病诊治年度进展2024
张煜轩
瞿介明
作者及单位信息
·
DOI： 10.3760/cma.j.cn112147-20241218-00744
Annual updates of respiratory infectious diseases in 2024
Zhang Yuxuan
Qu Jieming
Authors Info & Affiliations
Zhang Yuxuan
Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Institute of Respiratory Diseases, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China
Qu Jieming
Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Institute of Respiratory Diseases, School of Medicine, Shanghai Jiaotong University, Shanghai 200025, China
·
DOI： 10.3760/cma.j.cn112147-20241218-00744
1213
278
0
0
10
3
PDF下载
APP内阅读
摘要

2024年度，呼吸感染性疾病依然是全球公共健康的严峻挑战，抗生素耐药性、病程复杂性和传播广泛性共同加重了全球居民的疾病负担。与此同时，优先病原体清单的更新、多种病原体的“感染再现”现象等，为呼吸感染性疾病诊治带来了新的压力和挑战。过去1年，在感染病原学快速诊断技术研发、抗感染新药与疫苗的研发等领域有众多研究成果面世，本文就呼吸感染性疾病领域主要的研究进展进行回顾。

ABSTRACT

In 2024, respiratory infectious diseases continue to pose a pressing challenge to global public health, mainly due to antibiotic resistance, disease complexity, and widespread transmission, all of which will increase the global disease burden. In addition, the updated bacterial priority pathogens list and the resurgence of certain pathogens have added new layers of complexity to the diagnosis and treatment of respiratory infectious diseases Over the past year, significant progress has been achieved, particularly in rapid diagnostic technologies, the development of innovative anti-infective drugs, and the advancement of vaccines. This article provides an overview of the most important research advances in the field of respirator y infectious diseases.

Qu Jieming, Email: mocdef.3ab616090uqmj
Copyright by Chinese Medical Association
No content published by the journals of Chinese Medical Association may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journals without permission.
All articles published represent the opinions of the authors, and do not reflect the official policy of the Chinese Medical Association or the Editorial Board, unless this is clearly specified.
引用本文

张煜轩,瞿介明. 呼吸感染性疾病诊治年度进展2024[J]. 中华结核和呼吸杂志,2025,48(02)：149-153.

DOI:10.3760/cma.j.cn112147-20241218-00744

PERMISSIONS

Request permissions for this article from CCC.

评价本文
*以上评分为匿名评价

版权归中华医学会所有。

未经授权，不得转载、摘编本刊文章，不得使用本刊的版式设计。

除非特别声明，本刊刊出的所有文章不代表中华医学会和本刊编委会的观点。

2024年度（2023年10月1日至2024年9月30日），呼吸感染性疾病仍然威胁全人类生命健康。面对抗生素耐药与优先病原体清单的更新、多种病原体的“感染再现”现象等新的挑战，过去一年，在诊断技术、抗感染治疗、mRNA疫苗等领域亦有诸多研究成果面世。本文将从疾病流行现状、新型检验技术、抗感染药物开发和疾病预防康复4个方面，总结和回顾过去1年的重要研究进展，为未来呼吸感染性疾病防控与诊治的临床实践提供参考。
试读结束，您可以通过登录机构账户或个人账户后获取全文阅读权限。
参考文献
[1]
Zhang L , Xiao Y , Zhang G ,et al. Identification of priority pathogens for aetiological diagnosis in adults with community-acquired pneumonia in China: a multicentre prospective study[J]. BMC Infect Dis, 2023,23(1):231. DOI: 10.1186/s12879-023-08166-3 .
返回引文位置Google Scholar
百度学术
万方数据
[2]
何礼贤. 关注成人社区获得性肺炎病原学演变新动态[J]. 中华结核和呼吸杂志, 2024,47(6):576-581. DOI: 10.3760/cma.j.cn112147-20231024-00264 .
返回引文位置Google Scholar
百度学术
万方数据
[3]
Qu J , Zhang J , Chen Y ,et al. Aetiology of severe community acquired pneumonia in adults identified by combined detection methods: a multi-centre prospective study in China[J]. Emerg Microbes Infect, 2022,11(1):556-566. DOI: 10.1080/22221751.2022.2035194 .
返回引文位置Google Scholar
百度学术
万方数据
[4]
Martin-Loeches I , Reyes LF , Nseir S ,et al. European network for ICU-related respiratory infections (ENIRRIs): a multinational, prospective, cohort study of nosocomial LRTI[J]. Intensive Care Med, 2023,49(10):1212-1222. DOI: 10.1007/s00134-023-07210-9 .
返回引文位置Google Scholar
百度学术
万方数据
[5]
Network CS . CHINET Surveillance of bacterial resistance in China: respiratory pathogens report, january-june 2024[R]. CHINET Bacterial Resistance Monitoring:National Health Commission of the People′s Republic of China, 2024.
返回引文位置Google Scholar
百度学术
万方数据
[6]
World Health Organization. WHO bacterial priority pathogens list, 2024: bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance[M/OL]. [ 2024-5-17]. https://www.who.int/publications/i/item/9789240093461.
返回引文位置
[7]
中国疾病预防控制中心. 全国新型冠状病毒感染疫情情况[EB/OL].[ 2024-11-11]. https://m.chinacdc.cn/jksj/xgbdyq/202411/t20241111_302498.html.
返回引文位置Google Scholar
百度学术
万方数据
[8]
Centers for disease control and prevention. COVID data tracker: variant proportions[EB/OL]. [ 2024-12-7]. https://covid.cdc.gov/covid-data-tracker/#variant-proportions.
返回引文位置Google Scholar
百度学术
万方数据
[9]
European centre for disease prevention and control. The European respiratory virus surveillance summary (ERVISS)[EB/OL]. [ 2024-12-13]. https://www.ecdc.europa.eu/en/covid-19/variants-concern.
返回引文位置Google Scholar
百度学术
万方数据
[10]
World Health Organization. Global tuberculosis report 2024[M/OL]. [ 2024-10-29]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2024.
返回引文位置
[11]
Meyer Sauteur PM , Beeton ML , Europ ean society of clinical microbiology and infectious diseases (ESCMID) study GfMaCI ,et al. Mycoplasma pneumoniae: delayed re-emergence after COVID-19 pandemic restrictions[J]. Lancet Microbe, 2024,5(2):e100-e101. DOI: 10.1016/S2666-5247(23)00344-0 .
返回引文位置Google Scholar
百度学术
万方数据
[12]
Li H , Li S , Yang H ,et al. Resurgence of Mycoplasma pneumonia by macrolide-resistant epidemic clones in China[J]. Lancet Microbe, 2024,5(6):e515. DOI: 10.1016/S2666-5247(23)00405-6 .
返回引文位置Google Scholar
百度学术
万方数据
[13]
Yahong H , Mengyang G , Meng Q ,et al. Rising pertussis cases and deaths in China: current trends and clinical solutions[J]. Emerg Microbes Infect, 2024,13(1):2389086. DOI: 10.1080/22221751.2024.2389086 .
返回引文位置Google Scholar
百度学术
万方数据
[14]
Hu Y , Shi W , Meng Q ,et al. Detection of Bordetella spp. in children with pertussis-like illness from 2018 to 2024 in China[J]. J Infect, 2024,89(3):106222. DOI: 10.1016/j.jinf.2024.106222 .
返回引文位置Google Scholar
百度学术
万方数据
[15]
Centers for disease control and prevention. Pertussis (Whooping cough) surveillance[EB/OL].[ 2024-12-10]. https://www.cdc.gov/pertussis/php/surveillance/index.html.
返回引文位置Google Scholar
百度学术
万方数据
[16]
Smout E , Mellon D , Rae M . Whooping cough rises sharply in UK and Europe[J]. BMJ, 2024,385:q736. DOI: 10.1136/bmj.q736 .
返回引文位置Google Scholar
百度学术
万方数据
[17]
Mahase E . Whooping cough: over 3000 cases reported in Czech Republic so far this year[J]. BMJ, 2024,384:q729. DOI: 10.1136/bmj.q729 .
返回引文位置Google Scholar
百度学术
万方数据
[18]
Tanne JH . Whooping cough: Fivefold rise in US cases spells return to pre-pandemic levels[J]. BMJ, 2024,386:q2114. DOI: 10.1136/bmj.q2114 .
返回引文位置Google Scholar
百度学术
万方数据
[19]
Nordholm AC , Emborg HD , Nørgaard SK ,et al. Pertussis epidemic in Denmark, August 2023 to February 2024[J]. Euro Surveill, 2024,29(14):2400160. DOI: 10.2807/1560-7917.ES.2024.29.14.2400160 .
返回引文位置Google Scholar
百度学术
万方数据
[20]
Fu P , Yan G , Li Y ,et al. Pertussis upsurge, age shift and vaccine escape post-COVID-19 caused by ptxP3 macrolide-resistant Bordetella pertussis MT28 clone in China[J]. Clin Microbiol Infect, 2024,30(11):1439-1446. DOI: 10.1016/j.cmi.2024.08.016 .
返回引文位置Google Scholar
百度学术
万方数据
[21]
中国药师协会,中华医学会细菌感染与耐药防治分会,国家卫生健康委临床抗微生物药物敏感性折点研究和标准制定专家委员会. 病原宏基因组高通量测序临床本地化检测规范专家共识[J]. 中华预防医学杂志, 2024,58(4):454-465. DOI: 10.3760/cma.j.cn112150-20230720-00019 .
返回引文位置Google Scholar
百度学术
万方数据
[22]
Cao L , Yang H , Huang Z ,et al. Direct prediction of antimicrobial resistance in Pseudomonas aeruginosa by metagenomic next-generation sequencing[J]. Front Microbiol, 2024,15:1413434. DOI: 10.3389/fmicb.2024.1413434 .
返回引文位置Google Scholar
百度学术
万方数据
[23]
Hu X , Zhao Y , Han P ,et al. Novel clinical mNGS-based machine learning model for rapid antimicrobial susceptibility testing of acinetobacter baumannii[J]. J Clin Microbiol, 2023,61(5):e0180522. DOI: 10.1128/jcm.01805-22 .
返回引文位置Google Scholar
百度学术
万方数据
[24]
Xu Y , Liu D , Han P ,et al. Rapid inference of antibiotic resistance and susceptibility for Klebsiella pneumoniae by clinical shotgun metagenomic sequencing[J]. Int J Antimicrob Agents, 2024,64(2):107252. DOI: 10.1016/j.ijantimicag.2024.107252 .
返回引文位置Google Scholar
百度学术
万方数据
[25]
World Health Organization. WHO consolidated guidelines on tuberculosis: Module 1: Prevention-Tuberculosis preventive treatment, second edition[M/OL]. TB Targeted Next-Generation Sequencing for Drug Resistance Detection, 2024. https://www.ncbi.nlm.nih.gov/books/NBK607290/?report=classic.
返回引文位置Google Scholar
百度学术
万方数据
[26]
池细俤,高世华,张忠源,等. 微流控芯片恒温扩增技术快速检测多种呼吸道病原体的应用[J]. 中国实验诊断学, 2023,27(3):309-315. DOI: 10.3969/j.issn.1007-4287.2023.03.016 .
返回引文位置Google Scholar
百度学术
万方数据
[27]
Peng RB , Lu ZC , Liu M ,et al. RT-RPA-assisted CRISPR/Cas12a for rapid and multiplex detection of respiratory infectious viruses based on centrifugal microfluidics[J]. Sens Actuator B-Chem, 2024,399:134838. DOI: DOl:10.1016/i.snb.2023.134838 .
返回引文位置Google Scholar
百度学术
万方数据
[28]
Liu J , Li N , Zhang L ,et al. A wax interface-enabled one-pot multiplexed nucleic acid testing platform for rapid and sensitive detection of viruses and variants[J]. Small Methods, 2024,8(8):e2400030. DOI: 10.1002/smtd.202400030 .
返回引文位置Google Scholar
百度学术
万方数据
[29]
张天辉,马子淳,刘荣梅,等. 基于尿液的脂阿拉伯甘露聚糖抗原检测对肺结核的诊断价值[J]. 中华结核和呼吸杂志, 2024,47(2):132-136. DOI: 10.3760/cma.j.cn112147-20230814-00074 .
返回引文位置Google Scholar
百度学术
万方数据
[30]
Drain PK , Niu X , Shapiro AE ,et al. Real-world diagnostic accuracy of lipoarabinomannan in three non-sputum biospecimens for pulmonary tuberculosis disease[J]. EBioMedicine, 2024,108:105353. DOI: 10.1016/j.ebiom.2024.105353 .
返回引文位置Google Scholar
百度学术
万方数据
[31]
World Health Organization. Antibacterial agents in clinical and preclinical development: an overview and analysis[M/OL]. [ 2024-6-14]. https://www.who.int/publications/ i/item/9789240094000 .
返回引文位置
[32]
Kaye KS , Shorr AF , Wunderink RG ,et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK)[J]. Lancet Infect Dis, 2023,23(9):1072-1084. DOI: 10.1016/S1473-3099(23)00184-6 .
返回引文位置Google Scholar
百度学术
万方数据
[33]
Titov I , Wunderink RG , Roquilly A ,et al. A randomized, double-blind, multicenter trial comparing efficacy and safety of Imipenem/Cilastatin/Relebactam versus Piperacillin/Tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 study)[J]. Clin Infect Dis, 2021,73(11):e4539-e4548. DOI: 10.1093/cid/ciaa803 .
返回引文位置Google Scholar
百度学术
万方数据
[34]
Zampaloni C , Mattei P , Bleicher K ,et al. A novel antibiotic class targeting the lipopolysaccharide transporter[J]. Nature, 2024,625(7995):566-571. DOI: 10.1038/s41586-023-06873-0 .
返回引文位置Google Scholar
百度学术
万方数据
[35]
Pahil KS , Gilman M , Baidin V ,et al. A new antibiotic traps lipopolysaccharide in its intermembrane transporter[J]. Nature, 2024,625(7995):572-577. DOI: 10.1038/s41586-023-06799-7 .
返回引文位置Google Scholar
百度学术
万方数据
[36]
Kim MK , Chen Q , Echterhof A ,et al. A blueprint for broadly effective bacteriophage-antibiotic cocktails against bacterial infections[J]. Nat Commun, 2024,15(1):9987. DOI: 10.1038/s41467-024-53994-9 .
返回引文位置Google Scholar
百度学术
万方数据
[37]
Köhler T , Luscher A , Falconnet L ,et al. Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa[J]. Nat Commun, 2023,14(1):3629. DOI: 10.1038/s41467-023-39370-z .
返回引文位置Google Scholar
百度学术
万方数据
[38]
Shein A , Wannigama DL , Hurst C ,et al. Novel intranasal phage-CaEDTA-ceftazidime/avibactam triple combination therapy demonstrates remarkable efficacy in treating Pseudomonas aeruginosa lung infection[J]. Biomed Pharmacother, 2023,168:115793. DOI: 10.1016/j.biopha.2023.115793 .
返回引文位置Google Scholar
百度学术
万方数据
[39]
Lu H , Zhang G , Mao J ,et al. Efficacy and safety of GST-HG171 in adult patients with mild to moderate COVID-19: a randomised, double-blind, placebo-controlled phase 2/3 trial[J]. EClinicalMedicine, 2024,71:102582. DOI: 10.1016/j.eclinm.2024.102582 .
返回引文位置Google Scholar
百度学术
万方数据
[40]
Zhao S , Shang Y , Yin Y ,et al. Ziresovir in hospitalized infants with respiratory syncytial virus infection[J]. N Engl J Med, 2024,391(12):1096-1107. DOI: 10.1056/NEJMoa2313551 .
返回引文位置Google Scholar
百度学术
万方数据
[41]
Yu C , Qian H , Wu Q ,et al. Safety, pharmacokinetics, and food effect of sudapyridine (WX-081), a novel anti-tuberculosis candidate in healthy Chinese subjects[J]. Clin Transl Sci, 2024,17(2):e13718. DOI: 10.1111/cts.13718 .
返回引文位置Google Scholar
百度学术
万方数据
[42]
Diacon AH , Barry CE 3rd, Carlton A ,et al. A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial [J]. Nat Med, 2024,30(3):896-904. DOI: 10.1038/s41591-024-02829-7 .
返回引文位置Google Scholar
百度学术
万方数据
[43]
Wilson E , Goswami J , Baqui AH ,et al. Efficacy and safety of an mRNA-based RSV preF vaccine in older adults[J]. N Engl J Med, 2023,389(24):2233-2244. DOI: 10.1056/NEJMoa2307079 .
返回引文位置Google Scholar
百度学术
万方数据
[44]
Ehrmann S , Barbier F , Demiselle J ,et al. Inhaled amikacin to prevent ventilator-associated pneumonia[J]. N Engl J Med, 2023,389(22):2052-2062. DOI: 10.1056/NEJMoa2310307 .
返回引文位置Google Scholar
百度学术
万方数据
[45]
中国医师协会呼吸医师分会危重症学组,中华医学会呼吸病学分会. 重症新型冠状病毒感染合并侵袭性肺曲霉病和肺毛霉病诊治专家共识[J]. 中华结核和呼吸杂志, 2024,47(1):10-23. DOI: 10.3760/cma.j.cn112147-20230823-00098 .
返回引文位置Google Scholar
百度学术
万方数据
[46]
McGregor G , Sandhu H , Bruce J ,et al. Clinical effectiveness of an online supervised group physical and mental health rehabilitation programme for adults with post-covid-19 condition (REGAIN study): multicentre randomised controlled trial[J]. BMJ, 2024,384:e076506. DOI: 10.1136/bmj-2023-076506 .
返回引文位置Google Scholar
百度学术
万方数据
[47]
Longobardi I , Goessler K , de Oliveira Júnior GN ,et al. Effects of a 16-week home-based exercise training programme on health-related quality of life, functional capacity, and persistent symptoms in survivors of severe/critical COVID-19: a randomised controlled trial[J]. Br J Sports Med, 2023,57(20):1295-1303. DOI: 10.1136/bjsports-2022-106681 .
返回引文位置Google Scholar
百度学术
万方数据
[48]
Anidi IU , Kirenga B , Fennelly KP . Pulmonary rehabilitation for post-tuberculosis lung disease[J]. Am J Respir Crit Care Med, 2023,208(11):1246-1247. DOI: 10.1164/rccm.202309-1571LE .
返回引文位置Google Scholar
百度学术
万方数据
备注信息
A
瞿介明，Email： mocdef.3ab616090uqmj
B
张煜轩, 瞿介明. 呼吸感染性疾病诊治年度进展2024[J]. 中华结核和呼吸杂志, 2025, 48(2): 149-153. DOI: 10.3760/cma.j.cn112147-20241218-00744.
C
所有作者声明无利益冲突
D
四大慢病重大专项 (2023ZD0506200)
上海市重点专科项目 (shslczdzk02202)
上海市呼吸传染病应急防控与诊治重点实验室项目 (20dz2261100)
评论 （0条）
注册
登录
时间排序
暂无评论，发表第一条评论抢沙发
最新推荐
更多
多发性骨髓瘤肾损伤诊治指南（2024版）
中国医师协会血液科医师分会 等
中华内科杂志 2024,63(04)
中国心力衰竭诊断和治疗指南2024
中华医学会心血管病学分会 等
中华心血管病杂志 2024,52(03)
呼吸感染性疾病诊治年度进展2023
张国良 等
中华结核和呼吸杂志 2024,47(02)
呼吸感染性疾病诊治年度进展2022
杨清源 等
中华结核和呼吸杂志 2023,46(02)
MedAI助手（体验版）
文档即答
智问智答
机器翻译
回答内容由人工智能生成，我社无法保证其准确性和完整性，该生成内容不代表我们的态度或观点，仅供参考。
生成快照
文献快照

你好，我可以帮助您更好的了解本文，请向我提问您关注的问题。

0/2000

《中华医学会杂志社用户协议》 | 《隐私政策》

《SparkDesk 用户协议》 | 《SparkDesk 隐私政策》

网信算备340104764864601230055号 | 网信算备340104726288401230013号

技术支持：

历史对话
本文全部
还没有聊天记录
设置
模式
纯净模式沉浸模式
字号
小中大